AI Terminal
MaaT Pharma
Capital/Financing Update • Jul 5, 2024
1494_ir_2024-07-05_317db502-27b1-4daf-98ff-65bde4410886.pdf
Capital/Financing Update
Open in ViewerOpens in native device viewer
MaaT Pharma: Half-year Report and an Increase ofthe Resources Allocated to the Liquidity Contract With Kepler Cheuvreux
Lyon, France, July 5th , 2024 – 6:00 pm CET – MaaT Pharma (EURONEXT: MAAT – the "Company"), a clinicalstage biotechnology company and a leader in the development of Microbiome Ecosystem Therapies TM (MET) dedicated to enhancing survival for patients with cancer, today announces its half-year report on the liquidity contract with the firm Kepler Cheuvreux and an increase of €50,000 to the resources allocated to the contract, in accordance with the provisions of article 4 of AMF decision no. 2021-01 of June 22, 2021.
Under the liquidity contract entered into between Maat Pharma and Kepler Cheuvreux, the following resources appeared on the liquidity account on June 30th , 2024:
- 26,929 shares
- € 17,089.40
- Number of executions on buy side on semester: 933
- Number of executions on sell side on semester: 1,014
- Traded volume on buy side on semester: 28,959 shares for € 237,891.32
- Traded volume on sell side on semester: 26,266 shares for € 220,168.07
As a reminder:
- the following resources appeared on the last half year statement on December 31, 2023 on the liquidity account:
- 24,236 shares
- € 34,107.60
- Number of executions on buy side on semester: 627
- Number of executions on sell side on semester: 368
- Traded volume on buy side on semester: 18,328 shares for € 122,340.49
- Traded volume on sell side on semester: 9,576 shares for € 64,693.03
- the following resources appeared on the liquidity account when the activity started:
- 0 shares
- € 200,000.00
Following the addition of these resources for the amount of €50,000, the position on July 4th, 2024, is:
- 26,006 shares
- € 74,303.08
The implementation of this report is carried out in accordance with AMF Decision N°2021-01 of June 22nd , 2021, renewing the implementation of liquidity contracts for shares as an accepted market practice.
| Buy Side | Sell Side | |||||
|---|---|---|---|---|---|---|
| Number of executions |
Number of shares |
Traded volume in EUR |
Number of executions |
Number of shares |
Traded volume in EUR |
|
| Total | 933 | 28,959 | 237,891.32 | 1,014 | 26,266 | 220,168.07 |
| 01/02/2024 | - | - | - | 9 | 102 | 719.10 |
| 01/03/2024 | 3 | 60 | 448.80 | 15 | 435 | 3,275.55 |
| 01/04/2024 | 9 | 126 | 948.78 | 8 | 211 | 1,612.04 |
| 01/05/2024 | 2 | 45 | 339.30 | 3 | 90 | 689.40 |
| 01/08/2024 | 18 | 410 | 2,886.40 | - | - | - |
| 01/09/2024 | 11 | 340 | 2,237.20 | 15 | 425 | 2,843.25 |
| 01/10/2024 | 5 | 130 | 877.50 | 2 | 72 | 487.44 |
| 01/11/2024 | 2 | 2 | 13.74 | 10 | 241 | 1,679.77 |
| 01/12/2024 | 4 | 50 | 351.00 | 2 | 70 | 501.20 |
| 01/15/2024 | 8 | 203 | 1,408.82 | 8 | 110 | 779.90 |
| 01/16/2024 | 3 | 36 | 252.00 | 3 | 35 | 246.40 |
| 01/17/2024 | 5 | 70 | 482.30 | - | - | - |
| 01/18/2024 | 5 | 151 | 1,026.80 | - | - | - |
| 01/19/2024 | 10 | 222 | 1,469.64 | 1 | 30 | 201.00 |
| 01/22/2024 | 3 | 50 | 351.00 | 27 | 641 | 4,512.64 |
| 01/23/2024 | - | - | - | 5 | 93 | 672.39 |
| 01/24/2024 | 7 | 175 | 1,242.50 | 4 | 130 | 928.20 |
| 01/25/2024 | 5 | 71 | 506.94 | 2 | 36 | 257.76 |
| 01/26/2024 | 3 | 10 | 71.50 | 4 | 93 | 668.67 |
| 01/29/2024 | 7 | 141 | 1,022.25 | 8 | 155 | 1,148.55 |
| 01/30/2024 | 2 | 21 | 151.20 | 2 | 36 | 260.64 |
| 01/31/2024 | 4 | 110 | 784.30 | 6 | 148 | 1,061.16 |
| 02/01/2024 | 3 | 60 | 430.80 | 2 | 42 | 304.50 |
| 02/02/2024 | 8 | 160 | 1,142.40 | 8 | 150 | 1,087.50 |
| 02/05/2024 | - | - | - | 2 | 35 | 250.95 |
| 02/06/2024 | 3 | 70 | 497.00 | 5 | 105 | 753.90 |
| 02/07/2024 | 4 | 85 | 606.05 | - | - | - |
| 02/08/2024 | 2 | 21 | 149.94 | 5 | 83 | 593.45 |
| 02/09/2024 | 10 | 185 | 1,311.65 | 6 | 118 | 859.04 |
| 02/12/2024 | 7 | 127 | 896.62 | 1 | 1 | 7.22 |
| 02/13/2024 | 1 | 1 | 7.02 | 4 | 24 | 169.44 |
| 02/14/2024 | 4 | 69 | 481.62 | 2 | 32 | 227.20 |
| 02/15/2024 | 3 | 26 | 182.52 | 10 | 151 | 1,069.08 |
| 02/16/2024 | 2 | 30 | 213.00 | 3 | 41 | 293.15 |
| 02/19/2024 | 7 | 130 | 928.20 | 17 | 280 | 2,027.20 |
| 02/20/2024 | - | - | - | 15 | 329 | 2,470.79 |
| 02/21/2024 | 9 | 130 | 964.60 | - | - | - |
| 02/22/2024 | - | - | - | 9 | 115 | 865.95 |
| 02/23/2024 | 1 | 1 | 7.62 | 53 | 1,131 | 9,398.61 |
| 02/26/2024 | 26 | 550 | 4,526.50 | 9 | 103 | 850.78 |
| 02/27/2024 | 6 | 75 | 612.00 | 13 | 277 | 2,310.18 |
| 02/28/2024 | 45 | 880 | 6,758.40 | 23 | 706 | 5,655.06 |
| 02/29/2024 | 15 | 211 | 1,673.23 | 3 | 34 | 270.30 |
| 03/01/2024 | 4 | 90 | 711.00 | 10 | 200 | 1,606.00 |
| 03/04/2024 | 14 | 260 | 2,048.80 | 7 | 130 | 1,036.10 |
| 03/05/2024 | 9 | 162 | 1,263.60 | 10 | 133 | 1,046.71 |
| 03/06/2024 | 11 | 245 | 2,035.95 | 53 | 1,009 | 8,465.51 |
| 03/07/2024 | 2 | 20 | 170.40 | 21 | 260 | 2,236.00 |
| 03/08/2024 | 17 | 335 | 2,814.00 | 6 | 94 | 797.12 |
| 03/11/2024 | 7 | 114 | 992.94 | 22 | 381 | 3,341.37 |
| Buy Side | Sell Side | |||||
|---|---|---|---|---|---|---|
| Number of executions |
Number of shares |
Traded volume in EUR |
Number of executions |
Number of shares |
Traded volume in EUR |
|
| Total | 933 | 28,959 | 237,891.32 | 1,014 | 26,266 | 220,168.07 |
| 03/12/2024 | 7 | 139 | 1,234.32 | 10 | 316 | 2,837.68 |
| 03/13/2024 | 1 | 35 | 315.00 | 25 | 1,039 | 9,735.43 |
| 03/14/2024 | 30 | 921 | 8,427.15 | 13 | 319 | 2,992.22 |
| 03/15/2024 | 11 | 291 | 2,697.57 | 28 | 632 | 5,890.24 |
| 03/18/2024 | 5 | 99 | 903.87 | 3 | 45 | 413.55 |
| 03/19/2024 | - | - | - | 6 | 74 | 682.28 |
| 03/20/2024 | 20 | 553 | 4,943.82 | 13 | 328 | 2,971.68 |
| 03/21/2024 | 8 | 370 | 3,204.20 | 3 | 55 | 480.70 |
| 03/22/2024 | 6 | 125 | 1,113.75 | 19 | 422 | 3,798.00 |
| 03/25/2024 | 12 | 193 | 1,796.83 | 16 | 481 | 4,540.64 |
| 03/26/2024 | 6 | 158 | 1,448.86 | 8 | 173 | 1,600.25 |
| 03/27/2024 | 1 | 50 | 465.00 | 6 | 258 | 2,414.88 |
| 03/28/2024 | 22 | 692 | 6,304.12 | 8 | 343 | 3,217.34 |
| 04/02/2024 | 5 | 185 | 1,626.15 | 6 | 185 | 1,635.40 |
| 04/03/2024 | 4 | 56 | 495.60 | 1 | 1 | 8.86 |
| 04/04/2024 | - | - | - | 4 | 90 | 808.20 |
| 04/05/2024 | - | - | - | 17 | 435 | 4,023.75 |
| 04/08/2024 | 9 | 256 | 2,403.84 | 26 | 626 | 5,959.52 |
| 04/09/2024 | 8 | 133 | 1,263.50 | 10 | 444 | 4,253.52 |
| 04/10/2024 | - | - | - | 7 | 226 | 2,171.86 |
| 04/11/2024 | 2 | 36 | 342.00 | 5 | 33 | 316.47 |
| 04/12/2024 | 2 | 20 | 189.60 | 1 | 1 | 9.56 |
| 04/15/2024 | 41 | 1,314 | 12,246.48 | 25 | 785 | 7,622.35 |
| 04/16/2024 | 4 | 125 | 1,140.00 | 14 | 325 | 2,996.50 |
| 04/17/2024 | 13 | 578 | 5,138.42 | - | - | - |
| 04/18/2024 | 3 | 101 | 906.98 | 5 | 266 | 2,420.60 |
| 04/19/2024 | 21 | 1,779 | 15,726.36 | 7 | 304 | 2,723.84 |
| 04/22/2024 | 4 | 330 | 2,864.40 | 11 | 593 | 5,200.61 |
| 04/23/2024 | 3 | 124 | 1,088.72 | 6 | 157 | 1,389.45 |
| 04/24/2024 | 6 | 217 | 1,907.43 | 2 | 2 | 17.62 |
| 04/25/2024 | 1 | 1 | 8.80 | 12 | 468 | 4,165.20 |
| 04/26/2024 | 2 | 130 | 1,170.00 | 3 | 29 | 262.74 |
| 04/29/2024 | 6 | 285 | 2,676.15 | 20 | 652 | 6,109.24 |
| 04/30/2024 | 6 | 354 | 3,313.44 | 3 | 105 | 996.45 |
| 05/02/2024 | 5 | 221 | 2,048.67 | 2 | 80 | 747.20 |
| 05/03/2024 | 1 | 1 | 9.24 | 7 | 264 | 2,460.48 |
| 05/06/2024 | 10 | 323 | 3,007.13 | 4 | 91 | 849.94 |
| 05/07/2024 | 4 | 244 | 2,286.28 | 12 | 466 | 4,385.06 |
| 05/08/2024 | 1 | 20 | 188.00 | 1 | 5 | 47.30 |
| 05/09/2024 | - | - | - | 1 | 95 | 898.70 |
| 05/10/2024 | 6 | 161 | 1,513.40 | 2 | 39 | 368.94 |
| 05/13/2024 | 2 | 103 | 968.20 | 2 | 101 | 952.43 |
| 05/14/2024 | 2 | 77 | 719.18 | 2 | 84 | 788.76 |
| 05/15/2024 | 55 | 3,305 | 27,695.90 | 5 | 150 | 1,281.00 |
| 05/16/2024 | 7 | 340 | 2,692.80 | 9 | 260 | 2,072.20 |
| 05/17/2024 | 12 | 387 | 3,154.05 | 15 | 325 | 2,668.25 |
| 05/20/2024 | 8 | 325 | 2,665.00 | 7 | 205 | 1,693.30 |
| 05/21/2024 | 7 | 265 | 2,130.60 | 4 | 200 | 1,624.00 |
| 05/22/2024 | 11 | 344 | 2,752.00 | 3 | 88 | 719.84 |
| 05/23/2024 | 3 | 62 | 494.76 | 6 | 130 | 1,040.00 |
| Buy Side | Sell Side | |||||
|---|---|---|---|---|---|---|
| Number of executions |
Number of shares |
Traded volume in EUR |
Number of executions |
Number of shares |
Traded volume in EUR |
|
| Total | 933 | 28,959 | 237,891.32 | 1,014 | 26,266 | 220,168.07 |
| 05/24/2024 | 6 | 308 | 2,439.36 | 8 | 230 | 1,826.20 |
| 05/27/2024 | 1 | 15 | 119.10 | 2 | 80 | 640.80 |
| 05/28/2024 | 2 | 70 | 558.60 | 3 | 55 | 443.30 |
| 05/29/2024 | 8 | 212 | 1,704.48 | 5 | 129 | 1,046.19 |
| 05/30/2024 | 8 | 313 | 2,500.87 | 4 | 88 | 709.28 |
| 05/31/2024 | 8 | 451 | 3,598.98 | 1 | 1 | 8.04 |
| 06/03/2024 | 3 | 150 | 1,194.00 | 3 | 50 | 400.00 |
| 06/04/2024 | 6 | 200 | 1,586.00 | 4 | 110 | 875.60 |
| 06/05/2024 | 5 | 119 | 940.10 | 5 | 100 | 794.00 |
| 06/06/2024 | 7 | 250 | 1,970.00 | 1 | 1 | 7.94 |
| 06/07/2024 | 6 | 214 | 1,697.02 | 8 | 140 | 1,113.00 |
| 06/10/2024 | 9 | 305 | 2,400.35 | 1 | 40 | 316.80 |
| 06/11/2024 | 5 | 200 | 1,560.00 | 5 | 212 | 1,670.56 |
| 06/12/2024 | 3 | 105 | 807.45 | 1 | 50 | 385.00 |
| 06/13/2024 | 5 | 163 | 1,253.47 | 4 | 125 | 965.00 |
| 06/14/2024 | 17 | 440 | 3,291.20 | 2 | 57 | 434.91 |
| 06/17/2024 | 26 | 700 | 4,704.00 | 6 | 285 | 1,915.20 |
| 06/18/2024 | 3 | 60 | 403.80 | 7 | 355 | 2,410.45 |
| 06/19/2024 | 10 | 591 | 3,953.79 | 3 | 39 | 267.54 |
| 06/20/2024 | 4 | 68 | 450.84 | 7 | 150 | 1,009.50 |
| 06/21/2024 | 2 | 51 | 346.80 | 5 | 303 | 2,084.64 |
| 06/24/2024 | 1 | 19 | 131.10 | 7 | 174 | 1,211.04 |
| 06/25/2024 | 7 | 150 | 1,081.50 | 10 | 360 | 2,610.00 |
| 06/26/2024 | - | - | - | 26 | 944 | 7,174.40 |
| 06/27/2024 | 19 | 613 | 4,677.19 | 4 | 89 | 688.86 |
| 06/28/2024 | 23 | 904 | 6,535.92 | 4 | 187 | 1,357.62 |
About MaaT Pharma
MaaT Pharma, a clinical stage biotechnology company, has established a complete approach to restoring patient-microbiome symbiosis in oncology. Committed to treating cancer and graft-versus-host disease (GvHD), a serious complication of allogeneic stem cell transplantation, MaaT Pharma has launched, in March 2022, an open-label, single arm Phase 3 clinical trial in patients with acute GvHD, following the achievement of its proof of concept in a Phase 2 trial. Its powerful discovery and analysis platform, gutPrint®, enables the identification of novel disease targets, evaluation of drug candidates, and identification of biomarkers for microbiomerelated conditions. The company's Microbiome Ecosystem Therapies are produced through a standardized cGMP manufacturing and quality control process to safely deliver the full diversity of the microbiome, in liquid and oral formulations. MaaT Pharma benefits from the commitment of world-leading scientists and established relationships with regulators to support the integration of the use of microbiome therapies in clinical practice. MaaT Pharma is listed on Euronext Paris (ticker: MAAT).
Contacts
MaaT Pharma – Investor Relations Guilhaume DEBROAS, Ph.D. Head of Investor Relations +33 6 16 48 92 50 [email protected]
MaaT Pharma – Media Relations
Pauline RICHAUD Senior PR & Corporate Communications Manager +33 6 14 06 45 92 [email protected]
Trophic Communications Jacob VERGHESE or Desmond JAMES +49 151 7441 6179 [email protected]